JVM Co

JVM Co Cash Conversion Cycle

The Cash Conversion Cycle (CCC) of JVM Co (054950.KQ) as of Nov 4, 2026 is 49.36. In the previous year, Cash Conversion Cycle (CCC) was 110.39 — a change of -55.29% (lower).

Cash Conversion Cycle

49.36

YoY

-55.29%

Last updated:

Cash Conversion Cycle (CCC) of JVM Co is 2025 49.36 . Cash Conversion Cycle (CCC) of JVM Co was 2024 110.39 . It decreases by -55.29% lower compared to the previous year.

The JVM Co Cash Conversion Cycle history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Conversion Cycle
Date
Cash Conversion Cycle
Jan 1, 2018
131.64 KRW
Jan 1, 2019
89.64 KRW
Jan 1, 2020
76.25 KRW
Jan 1, 2021
52.73 KRW
Jan 1, 2022
86.76 KRW
Jan 1, 2023
93.03 KRW
Jan 1, 2024
110.39 KRW
Jan 1, 2025
49.36 KRW
The JVM Co Cash Conversion Cycle history
YEARCash Conversion CycleYoY
49.36-55.29%
110.39+18.67%
93.03+7.23%
86.76+64.54%
52.73-30.85%
76.25-14.94%
89.64-31.90%
131.64-14.42%
153.82+8.26%
142.08+6.23%
133.75-10.81%
149.97—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

JVM Co Stock analysis

What does JVM Co do? JVM Co., Ltd. manufactures pharmacy automation systems under the brand JVM, targeting domestic and overseas markets. The company's primary products include automatic tablet dispensing and packaging systems (ATDPSs), automatic tablet classification and packing machines available in slide, box, and drum types, total safety solutions, automatic medication vision inspection systems (VIZENs), automatic package cutting and winding systems (WIZERs), and automatic medication sorting and control systems (AccuPharm). These products are sold to customers in the pharmaceutical and healthcare sectors seeking efficient automation solutions for medication handling and safety. The firm generates revenue through the sale of its branded automation systems, with a focus on domestic distribution and international markets. JVM's product portfolio addresses key operational needs in pharmacy settings, including dispensing, classification, inspection, and sorting of medications, ensuring compliance with safety standards while improving workflow efficiency. The company's offerings are designed to meet the demands of healthcare providers and pharmaceutical manufacturers requiring advanced automation technologies. JVM's business model centers on providing comprehensive automation solutions for pharmacy operations, leveraging its established brand JVM to differentiate its products in the market. By offering a wide range of specialized systems, the company caters to both domestic and international clients seeking reliable, high-quality automation equipment for medication management and safety protocols. JVM Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about JVM Co stock

Cash Conversion Cycle (CCC) of JVM Co is 49.36 in 2025.

Cash Conversion Cycle (CCC) of JVM Co changed from 110.39 to 49.36, representing a -55.29% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Cash Conversion Cycle (CCC) JVM Co since 2006 – with annual values, charts, and detailed analysis.

The Cash Conversion Cycle measures how long it takes to convert inventory investments into cash from sales. A shorter CCC indicates more efficient working capital management.

CCC = DSO + DIO - DPO

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Conversion Cycle (CCC)'s JVM Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Conversion Cycle (CCC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Conversion Cycle (CCC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — JVM Co

All Key Metrics — JVM Co